Related Experiment Video
Updated: May 2, 2026

Use of Enzymatic Biosensors to Quantify Endogenous ATP or H2O2 in the Kidney
Published on: October 12, 2015
Response of angiopoietin-like proteins 3 and 4 to hemodialysis
Dana Mahmood1, Elena Makoveichuk, Solveig Nilsson
11 Department of Public Health and Clinical Medicine Umeå University, Umeå - Sweden.
Insights
Angiopoietin-like proteins 3 and 4 (ANGPTL3/4) are elevated in chronic hemodialysis (cHD) patients. High-flux hemodialysis partially removed ANGPTL4, while citrate anticoagulation reduced ANGPTL4 levels.
Area of Science:
- Nephrology
- Endocrinology
- Lipid Metabolism
Background:
- Patients on chronic hemodialysis (cHD) exhibit reduced lipoprotein lipase (LPL) activity.
- Angiopoietin-like proteins (ANGPTL) 3 and 4 are known LPL inhibitors.
Purpose of the Study:
- To investigate plasma levels of ANGPTL3 and ANGPTL4 in cHD patients.
- To evaluate the impact of cHD on ANGPTL levels.
Main Methods:
- Cross-over study comparing citrate and tinzaparin anticoagulation in cHD patients (n=23) and controls (n=23).
- Analysis of ANGPTL3, ANGPTL4, LPL, and triglycerides.
- Samples analyzed during low-flux and high-flux hemodialysis (HD), and ultrafiltrate (UF).
Main Results:
- ANGPTL3 and ANGPTL4 levels were significantly higher in cHD patients compared to controls.
- ANGPTL4 levels increased during cHD and decreased after 180 minutes of HD.
- High-flux HD partially removed ANGPTL4, detected in UF, while low-flux HD did not.
- Citrate anticoagulation led to decreased ANGPTL4 levels, unlike tinzaparin which caused ANGPTL4 release.
Conclusions:
- Elevated ANGPTL3 and ANGPTL4 are observed in cHD patients.
- Tinzaparin anticoagulation during cHD releases ANGPTL4 from tissues.
- High-flux filters partially clear ANGPTL4, and citrate reduces its levels.
Background/Aim:
Patients on chronic hemodialysis (cHD) have decreased activity of lipoprotein lipase (LPL). Angiopoietin-like proteins (ANGPTL) 3 and 4 have been shown to inactivate LPL. The aim of this study was to investigate the levels of the ANGPTLs in plasma of cHD-patients and to evaluate if cHD may alter these levels.
Material And Methods:
Baseline data were collected from cHD patients (n = 23), and controls (n = 23) and samples were analyzed from 17 patients during low-flux or high-flux HD, and from ultrafiltrate (n = 5). The levels of ANGPTL3 and 4, LPL and triglycerides were studied in a cross-over design on cHD with local citrate compared to tinzaparin as anticoagulant.
Results:
The level of ANGPTL3 was higher than ANGPTL4 in patients and controls (p<0.01); the ANGPTL3 was 2.0 and ANGPTL4 was 3.3-fold higher in cHD versus controls. The levels of ANGPTL4 increased during cHD. After 180 min of HD the values had decreased again. When the dialysis was performed with high-flux filter, the mean level of ANGPTL4 at 180 min was below the value observed before cHD (p = 0.003). There was immunoreaction for ANGPTL4 in UFs when using high-flux, but not with low-flux, filter. ANGPTL3 was not detectable in UF. On cHD with citrate, no LPL activity was released into the blood.
Conclusions:
ANGPTL3 and ANGPTL4 were increased in HD patients. Anticoagulation with tinzaparin during cHD causes release of ANGPTL4 from tissues into blood. cHD using high-flux filters, to some extent, removed ANGPTL4. With citrate the levels of ANGPTL4 decreased.
Related Concept Videos
Regulation of Angiogenesis and Blood Supply
Hemodialysis I: Introduction
Hormonal Regulation
Hemodialysis III: Nursing Management
Hemodialysis II: Procedure and Complications
Endocrine Signaling

